为GTR应用准备和优化基于蛋膜的生物材料
Lohitha Kalluri1, Jason A Griggs1, Amol V Janorkar1
1Department of Biomedical Materials Science, School of Dentistry, University of Mississippi Medical Center, Jackson, MS 39216, USA.
概括
这项研究开发了一种新的,具有成本效益的由可溶性蛋膜蛋白 (SEP) 来导向组织再生 (GTR) 膜. 这种新的基于SEP的膜显示出作为代价昂贵的原体膜用于牙周再生的环保替代品的潜力.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 组织工程是组织工程.
背景情况:
- 导向组织再生 (GTR) 膜对于牙周组织修复至关重要.
- 目前基于原的GTR膜价格昂贵,限制了患者的访问和医疗保健系统的效率.
- 需要为传统的GTR膜提供具有成本效益和生物仿真性的替代品.
研究的目的:
- 开发一种使用可溶性蛋膜蛋白 (SEP) 的新型,经济和仿生GTR膜.
- 结合聚 (乳糖-co-甘油酸) (PLGA) 和纳米-酸 (HAp) 来增强机械和生物特性.
- 评估基于SEP的膜作为原膜的可持续替代品的潜力.
主要方法:
- 使用Taguchi直角阵列设计,选机械性能的显著因素.
- 通过响应表面方法来优化膜组成.
- 用SEM,EDAX,ATR-FTIR来表征膜,并评估人类牙周带纤维细胞 (HPLF) 的增殖.
主要成果:
- 预测最大拉伸强度为3.1 MPa,模量为39.9 MPa,重量为8.9%的PLGA,7.2%的SEP和2重%的HAp.
- 与组织培养聚氨酸和商业原膜相比,优化的PLGA/SEP/HAp膜表现出更高的HPLF增殖率.
- 开发的膜显示出有前途的机械强度和生物相容性.
结论:
- 可溶性蛋膜蛋白 (SEP) 可用于创建具有成本效益的纳米纤维GTR膜.
- 基于SEP的膜是一种有希望的,环保的,经济可行的替代品,可以替代当前基于原蛋白的GTR产品.
- 这项创新可以提高患者的可访问性,并降低牙周再生的医疗保健费用.
相关概念视频
00:53Transgenic Organisms
Overview
02:50Transgenic Plants
Recombinant DNA technology called transgenesis is often used to add a foreign gene or remove a detrimental gene from an organism. Such genetically modified organisms are called transgenic organisms.
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...
The first-ever transgenic plant was a tobacco plant developed in 1983 that showed resistance against the tobacco mosaic virus. Since then, many transgenic plants have been developed and commercialized for improving the agricultural, ornamental, and horticultural value of a crop plant. Transgenic...